Literature DB >> 6344900

Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948).

R M Rudd, A R Gellert, P R Studdy, D M Geddes.   

Abstract

M&B 22,948 (2-o-propoxyphenyl-8-azapurin-6-one) is an orally absorbed mast cell stabilizer which is 30 times as potent as disodium cromoglycate in laboratory and animal studies. In a double-blind placebo-controlled cross-over trial we studied the protection afforded by a single oral dose of 10 mg of M&B 22,948 against asthma induced by histamine and exercise, each in 12 patients. Compared with placebo the drug had no significant effect on the response to inhaled histamine but significantly inhibited the fall in FEV1 induced by exercise on treadmill (P less than 0.005). The exercise-induced fall in FEV1 was less following M&B 22,948 than placebo in all patients and the fall was inhibited by more than 50% in five (42%) of 12 patients. The degree of inhibition was significantly correlated with the plasma drug concentration (r = 0.65, P less than 0.025). M&B 22,948 merits evaluation in the treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344900

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  8 in total

1.  PDE11A associations with asthma: results of a genome-wide association scan.

Authors:  Andrew T DeWan; Elizabeth W Triche; Xuming Xu; Ling-I Hsu; Connie Zhao; Kathleen Belanger; Karen Hellenbrand; Saffron A G Willis-Owen; Miriam Moffatt; William O C Cookson; Blanca E Himes; Scott T Weiss; W James Gauderman; James W Baurley; Frank Gilliland; Jemma B Wilk; George T O'Connor; David P Strachan; Josephine Hoh; Michael B Bracken
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

Review 2.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

4.  Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.

Authors:  P G Bardin; M A Dorward; F C Lampe; B Franke; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 5.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 6.  Mechanisms of exercise-induced asthma.

Authors:  E Bar-Yishay; S Godfrey
Journal:  Lung       Date:  1984       Impact factor: 2.584

Review 7.  The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.

Authors:  A S Elhwuegi
Journal:  Ann Med Health Sci Res       Date:  2016 May-Jun

Review 8.  Mast cells in vulnerable atherosclerotic plaques--a view to a kill.

Authors:  Ken A Lindstedt; Mikko I Mäyränpää; Petri T Kovanen
Journal:  J Cell Mol Med       Date:  2007 Jul-Aug       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.